Free Trial

Oruka Therapeutics (NASDAQ:ORKA) Trading 7.4% Higher - What's Next?

Oruka Therapeutics logo with Medical background

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report)'s share price traded up 7.4% during mid-day trading on Monday . The company traded as high as $13.40 and last traded at $13.54. 127,068 shares were traded during trading, a decline of 46% from the average session volume of 234,912 shares. The stock had previously closed at $12.60.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 15th. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. Finally, BTIG Research initiated coverage on shares of Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $40.38.

Read Our Latest Stock Report on ORKA

Oruka Therapeutics Stock Performance

The stock has a market cap of $526.78 million, a P/E ratio of -3.12 and a beta of -0.34. The company's 50 day moving average price is $11.41 and its 200-day moving average price is $11.96.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Several institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth $54,000. Squarepoint Ops LLC bought a new position in Oruka Therapeutics during the fourth quarter valued at about $236,000. Wellington Management Group LLP grew its position in Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after buying an additional 12,952 shares during the period. Charles Schwab Investment Management Inc. bought a new position in Oruka Therapeutics during the fourth quarter valued at about $303,000. Finally, AlphaQuest LLC bought a new position in Oruka Therapeutics during the first quarter valued at about $168,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Recommended Stories

Should You Invest $1,000 in Oruka Therapeutics Right Now?

Before you consider Oruka Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.

While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines